Nexus Pharmaceuticals Receives FDA Approval for Isoproterenol Hydrochloride Injection USP
Nexus Pharmaceuticals announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Isoproterenol…
Read More...
Read More...
